A study published in JAMA found that patients with SGLT2i-associated ketoacidosis receive significantly lower insulin doses compared to those with Type 1 Diabetes (T1D) ketoacidosis. The study highlights the importance of personalized treatment for different types of diabetic ketoacidosis. The findings suggest that insulin dosages should be adjusted based on the specific underlying cause of ketoacidosis. Furthermore, the study emphasizes the need for individualized treatment plans for patients with different types of diabetes-related complications.
Source link
SGLT2i-associated ketoacidosis patients receive significantly lower insulin doses vs those with T1D ketoacidosis: JAMA
